A Cornell-led collaboration devised a potentially low-cost method for producing antibodies for therapeutic treatments: bioengineered bacteria with an overlooked enzyme that can help monoclonal antibodies boost their immune defenses.
Cornell researchers have identified an antibiotic, rifampin, that is 99.9% effective against Salmonella Typhi, the bacterium that causes typhoid fever.
The Center for Teaching Innovation will host “What Works,” on Oct. 1, featuring presentations, the Canvas Course Spotlight awardees, and a poster showcase that will demonstrate engaged learning approaches from Cornell faculty teaching in a diverse range of courses and fields.
Researchers developed machine-learning models that can sift through cell-free RNA and identify key biomarkers for chronic fatigue syndrome, a debilitating disease that is difficult to confirm in patients because its symptoms can be easily confused with those of other illnesses.
Cornell researchers have developed an implant system that can treat Type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression.